Ovid Therapeutics (OVID) Capital Expenditures (2016 - 2024)

Ovid Therapeutics (OVID) has reported Capital Expenditures for 9 consecutive years, with -$26000.0 the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Capital Expenditures fell 100.0% year-over-year to -$26000.0; the trailing twelve-month figure through Sep 2025 stood at -$26000.0 (down 125.24% YoY), and the FY2024 full-year result was $90000.0, down 7.22% from the prior year.
• Capital Expenditures declined to -$26000.0 in Q4 2024 per OVID's latest filing, from $97000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.0 million in Q2 2022 and bottomed at -$26000.0 in Q4 2024.
• Historically, Capital Expenditures has averaged $103268.2 across 5 years, with a median of $21000.0 in 2020.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 103990400.0% in 2022, then slumped 110.84% in 2023.
• Over 5 years, Capital Expenditures stood at $48598.0 in 2020, then jumped by 233.26% to $161958.0 in 2021, then decreased by 25.94% to $119939.0 in 2022, then sank by 110.84% to -$13000.0 in 2023, then tumbled by 100.0% to -$26000.0 in 2024.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$26000.0, $97000.0, and $19000.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.